IO Biotech, Inc.

NasdaqGS:IOBT Stock Report

Market Cap: US$13.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IO Biotech Management

Management criteria checks 2/4

IO Biotech's CEO is MBZ Zocca, appointed in Jan 2015, has a tenure of 11.17 years. total yearly compensation is $1.84M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $14.76K. The average tenure of the management team and the board of directors is 3.2 years and 4.4 years respectively.

Key information

MBZ Zocca

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage30.86%
CEO tenure11.2yrs
CEO ownership0.1%
Management average tenure3.2yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 11

IO Biotech's Phase 3 Trial Fails To Deliver

Summary IO Biotech has been anticipating an important phase 3 trial readout for their novel immunotherapy candidate in melanoma. IOBT's topline data showcase "clinically positive," but statistically insignificant results. This article considers the updated investment thesis based on this readout, potential subgroups, and the dwindling cash reserves. Read the full article on Seeking Alpha
Analysis Article • Apr 02

Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 17

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jun 12

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 10

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 15

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 20

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

IO Biotech names new CFO

IO Biotech (NASDAQ:IOBT) announced Thursday the appointment of Amy Sullivan as its new chief financial officer.  Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer. Earlier, Sullivan was chief strategy officer for Euronext-listed Kiadis Pharma where she was responsible for all aspects of fundraising and capital formation strategy.
Analysis Article • Sep 27

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

IO Biotech GAAP EPS of -$0.64

IO Biotech press release (NASDAQ:IOBT): Q2 GAAP EPS of -$0.64. Cash and cash equivalents at June 30, 2022 were $170.1 million, compared to $211.5 million at December 31, 2021. Cash on hand is expected to support operations through anticipated data readouts into mid-2024.
Analysis Article • Jun 14

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 25

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has MBZ Zocca's remuneration changed compared to IO Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$88m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$98m

Dec 31 2024US$2mUS$568k

-US$95m

Sep 30 2024n/an/a

-US$90m

Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$88m

Dec 31 2023US$2mUS$541k

-US$86m

Sep 30 2023n/an/a

-US$80m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$734kUS$515k

-US$71m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$8mUS$399k

-US$75m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$409kUS$307k

-US$15m

Compensation vs Market: MBZ's total compensation ($USD1.84M) is above average for companies of similar size in the US market ($USD630.05K).

Compensation vs Earnings: MBZ's compensation has increased whilst the company is unprofitable.

CEO

MBZ Zocca (57 yo)

11.2yrs
Tenure
US$1,839,811
Compensation

Dr. Mai-Britt Zocca, Ph D, also known as MBZ, was also the Founder and Chief Executive Officer of Onconox ApS since July 2011 until May 2019. She served as Director at Valo Therapeutics Ltd since June 2020...

Leadership Team

NamePositionTenureCompensationOwnership
Mai-Britt Zocca
Founder11.2yrsUS$1.84m0.11%
$ 14.8k
Amy Sullivan
Principal Accounting Officer & CFO3.4yrsUS$998.41k0.12%
$ 16.3k
Inge Svane
Founder & Clinical Advisorno datano datano data
Mads Andersen
Co-Founder & Scientific Advisorno datano datano data
Anders Ljungqvist
Founderno datano datano data
Per Straten
Founderno datano datano data
Eric Faulkner
Chief Technical Officer2.7yrsno datano data
Devin Smith
Secretary3.2yrsUS$917.30k0.024%
$ 3.3k
Daniel Mannix
Senior Vice President of Regulatory Affairs4.2yrsno datano data
Faical Miyara
Chief Business Officer1.9yrsno datano data
Marjan Shamsaei
Senior VP of Commercial Development & Portfolio Lead1.9yrsno datano data
3.2yrs
Average Tenure
57yo
Average Age

Experienced Management: IOBT's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mai-Britt Zocca
Founder4.4yrsUS$1.84m0.11%
$ 14.8k
Inge Svane
Founder & Clinical Advisorno datano datano data
Mads Andersen
Co-Founder & Scientific Advisorno datano datano data
David Smith
Independent Director4.1yrsUS$97.57k0%
$ 0
K. Hirth
Independent Chairman9.5yrsUS$122.90k0%
$ 0
Christian Elling
Independent Director10.3yrsUS$92.07k0%
$ 0
Kathleen Glaub
Independent Director7.8yrsUS$102.07k0%
$ 0
Alexander Maximiliaan Eggermont
Sr. Clinical Advisor & Member of the Scientific Advisory Boardno datano datano data
Kapil Dhingra
Strategic Advisory Board Memberno datano datano data
Helen Collins
Independent Director2.3yrsUS$82.07k0%
$ 0
Heidi Hunter
Independent Director2.6yrsUS$93.57k0.021%
$ 2.9k
4.4yrs
Average Tenure
65.5yo
Average Age

Experienced Board: IOBT's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/30 13:51
End of Day Share Price 2026/03/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IO Biotech, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher HowertonJefferies LLC
Roger SongJefferies LLC